FDA, AstraZeneca and Breast Cancer

AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer
AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), in patients with a certain type of breast cancer. The drug, developed in partnership with Japan-based Daiichi Sankyo,
FDA Approves Metastatic Breast Cancer Drug, Datroway
The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) to treat unresectable or metastatic hormone receptor HR+, HER2- breast cancer in adult patients who have previously received endocrine-based therapy and chemotherapy for unresectable or metastatic disease, according to a news release.
US FDA approves AstraZeneca's drug for breast cancer
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday.
Considering Sacituzumab in HR+, HER2- Breast Cancer After Progression
During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic breast cancer who had progressed on multiple line of therapy.
FDA Okays AstraZeneca And Daiichi's Datroway For Metastatic HR-Positive, HER2-Negative Breast Cancer
The U.S. Food and Drug Administration approved AstraZeneca (AZN, AZN.L) and Daiichi Sankyo's (DSKYF.PK) Datroway (datopotamab
ZME Science on MSN5h
New AI Blood Test with Lasers Finds Breast Cancer in Its Earliest Stage
Even if a patient is unable to beat the disease, early-stage detection of cancer can play a crucial role in increasing their ...
I'm A Breast Cancer Doctor. Here's What I Didn't Know — Until I Was Diagnosed Myself.
Having counseled thousands of patients through their breast cancer diagnosis, I was fully aware of how nondiscriminatory this ...
Hosted on MSN1h
Heart Patients Are At An Increased Risk Of Advanced Breast Cancer- Here’s How To Protect Yourself
Heart disease increases the likelihood of advanced breast cancer. Hormone receptor-positive tumors are linked to ...
Breast Cancer Rates Climb Among Younger Women
The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — ...
The Power of Personalized Breast Cancer Care
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
The American Journal of Managed Care7d
Identifying Patients With Low-Risk Breast Cancer for De-escalated Therapy
A new analysis of the Breast Cancer Index (BCI) may help identify women with HR-positive breast cancer who could potentially ...
Cure Today1d
Long-Term Patient Care Focuses on Precision-Based Therapy in Breast Cancer
Dr. Maxwell Lloyd discusses the long-term management of patients with HR-positive, HER2-negative breast cancer who have received Orserdu treatment.
Medscape4d
Drugmakers Are Limiting Cancer Patients’ Access to Financial Lifelines. Why?
Several major drugmakers have restricted commercially insured patients from their patient assistance programs, leaving ...